Which startups have raised the most funding in the mental health market?
Download our beautiful pitch about the mental health market

In our mental health market deck, you will find everything you need to understand the market
The mental health market has become one of the most funded areas in digital health, behavioral care, neuropsychiatry and psychedelic medicine.
This ranking is built for investors, founders and analysts who want a simple view of the most capitalized startups in the space.
We update this list every month, so the ranking stays close to the latest public funding data.
And if you want to better understand this new industry, you can download our pitch covering the mental health market.
A quick summary table
| Metric | Value |
|---|---|
| Most funded startup | Lyra Health, with $900M raised |
| Second most funded startup | atai Life Sciences, with $778M raised |
| Largest funding round | Cerebral, with a $300M Series C, tied with Charlie Health’s $300M Series C |
| Median funding | About $68M among ranked startups after excluding low-confidence records |
| Share of funding captured by the top 10 | About 43% of disclosed funding in the filtered ranking |
| Median time since last round | Roughly 3 years, based on disclosed or partially disclosed latest rounds |
| Startups that raised funding in the last 12 months | At least 13 startups, mainly in psychedelics, neurotechnology and specialty behavioral care |
| Mental health platform funding concentration | Lyra Health, Spring Health, Charlie Health, Cerebral and Talkspace all raised $300M or more |
| Psychedelic and neuropsychiatry capital | atai, MindMed, Cybin, Compass, Bright Minds, Lykos, Beckley and Draig raised about $2.9B combined |
| Behavioral care investor signal | Employer, payer and specialty care models remain strongly represented among the best-funded private companies |

This chart, featured in our mental health market deck, illustrates yearly VC investment in mental health startups
Top startups in the mental health market ranked by total funding raised
Here is an updated table that ranks the top startups in the mental health market based on the total amount of funding they have raised to date.
The table also includes the total number of funding rounds, the date and size of the latest round, the financing type (e.g. Series A, equity financing), key investors, the startup’s current status (active, IPO, acquired, or shut down), and a confidence score based on the data collected (we excluded startups with very low data confidence, to make sure everything is reliable).
If you're interested in knowing how much these startups are worth, you can check our list of the top startups in the mental health market ranked by valuation.
| # | Startup | What They Do | Total Raised ($) | Total Rounds | Last Round Date | Last Round Amount ($) | Last Round Type | Key Investors | Current Stage | Confidence |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lyra Health | Employer mental health platform | $900M | 7 | Undisclosed 2023 | $235M | Extension | Coatue, IVP, Sands Capital | Active | Strong |
| 2 | atai Life Sciences | Psychedelic mental health therapeutics | $778M | 8 | October 2025 | $150M | Public offering | Ferring Ventures, Apeiron Investment Group, Thiel Capital | IPO | Strong |
| 3 | MindMed | Psychedelic brain health therapies | $700M | 9 | November 2025 | $259M | Public offering | Deep Track Capital, Commodore Capital, Public investors | IPO | Strong |
| 4 | Cybin / Helus Pharma | Psychedelic neuropsychiatry drug developer | $486M | 8 | June 2026 | $50M | Public offering | Cantor, Barclays, Bloom Burton | IPO | Strong |
| 5 | Spring Health | Mental health benefits platform | $450M | 6 | Undisclosed 2023 | $220M | Series E | Tiger Global, Northzone, Kinnevik | Active | Strong |
| 6 | Charlie Health | Virtual intensive mental care | $404M | 4 | Undisclosed 2024 | $300M | Series C | Apogee Capital, General Atlantic, SVB Capital | Active | Partial |
| 7 | Cerebral | Online psychiatry platform | $300M | 4 | Undisclosed 2022 | $300M | Series C | SoftBank, Oak HC/FT, Silver Lake | Active | Partial |
| 8 | Compass Pathways | Psychedelic therapy biotech | $300M | 4 | Undisclosed 2020 | $100M | IPO | ATAI Life Sciences, Peter Thiel, Novartis | IPO | Full |
| 9 | Talkspace | Online therapy platform | $300M | 5 | Undisclosed 2021 | $220M | SPAC IPO | Spark Capital, Norwest, Qumra | IPO | Full |
| 10 | Cortica | Autism whole-child care provider | $255M | 4 | November 2024 | $80M | Strategic equity | Morgan Health, Nexus NeuroTech Ventures, Autism Impact Fund | Active | Strong |
| 11 | Cognito Therapeutics | Alzheimer’s neurotechnology therapy | $233M | 4 | March 2026 | $105M | Series C | Morningside Ventures, IAG Capital Partners, Starbloom Capital | Active | Strong |
| 12 | Bright Minds Biosciences | 5-HT neuroscience drug developer | $232M | 10 | January 2026 | $175M | Public offering | Cormorant, RA Capital, Perceptive | IPO | Strong |
| 13 | Akili Interactive | Prescription digital therapeutics games | $230M | 5 | May 2021 | $110M | Series D | Neuberger Berman, Polaris Partners, Shionogi | Acquired | Partial |
| 14 | Headway | Therapist insurance marketplace | $225M | 5 | Undisclosed 2023 | $13M | Extension | a16z, Accel, Thrive Capital | Active | Strong |
| 15 | Alma | Therapist insurance enablement platform | $221M | 5 | August 2022 | $130M | Series D | Thoma Bravo, Cigna Ventures, Insight Partners | Acquired | Strong |
| 16 | Brightline | Pediatric virtual behavioral care | $205M | 5 | July 2022 | $10M | Series C extension | Northwell Health, KKR, GV | Active | Strong |
| 17 | SonderMind | Therapy matching care platform | $183M | 4 | July 2021 | $150M | Series C | Drive Capital, Premji Invest, General Catalyst | Active | Full |
| 18 | Quartet Health | Care coordination platform | $160M | 5 | Undisclosed 2021 | Undisclosed | Acquisition | GV, Oak HC/FT, Centene | Acquired | Strong |
| 19 | Big Health | Digital mental health therapeutics | $153M | 5 | February 2026 | $24M | Series C extension | .406 Ventures, AlleyCorp, SoftBank Vision Fund 2 | Active | Partial |
| 20 | Pelago | Virtual substance-use treatment | $151M | 7 | March 2024 | $58M | Series C | Atomico, Kinnevik, Octopus Ventures | Active | Partial |
| 21 | Talkiatry | Psychiatry telehealth | $150M | 3 | Undisclosed 2023 | $130M | Growth | a16z, Left Lane, Perceptive | Active | Partial |
| 22 | Lykos Therapeutics | MDMA-assisted PTSD therapy | $150M | 2 | May 2025 | $50M | Series B | Gracias Family Foundation, CH Foundation | Active | Strong |
| 23 | Click Therapeutics | Prescription digital therapeutics software | $150M | 5 | April 2026 | $50M | Series D | Boehringer Ingelheim, H.I.G. BioHealth, Sanofi Ventures | Active | Strong |
| 24 | Beckley Psytech | Short-duration psychedelic medicines | $142M | 4 | January 2024 | $40M | Strategic equity | atai Life Sciences | Acquired | Strong |
| 25 | Draig Therapeutics | Neuropsychiatric drug developer | $140M | 1 | June 2025 | $140M | Series A | Access Biotechnology, Canaan Partners, SV Health Investors | Active | Strong |
| 26 | Workit Health | Virtual addiction treatment | $136M | 4 | October 2021 | $118M | Series C | Insight Partners, CVS Health Ventures, FirstMark Capital | Active | Partial |
| 27 | Gilgamesh Pharmaceuticals | Neuropsychiatric small-molecule drugs | $129M | 5 | March 2026 | $60M | Series A | Satori Neuro, Prime Movers Lab | Active | Partial |
| 28 | Eleos Health | Behavioral health AI documentation | $128M | 5 | January 2025 | $60M | Series C | Greenfield Partners, F-Prime Capital, Eight Roads | Active | Full |
| 29 | Woebot Health | AI mental health chatbot platform | $124M | 4 | March 2022 | $10M | Strategic investment | Leaps by Bayer, JAZZ Venture Partners, Temasek | Active | Partial |
| 30 | Happify Health / Twill | Digital therapeutic care platform | $122M | 10 | March 2021 | $73M | Series D | Deerfield Management, Omega Capital Partners, ION Crossover Partners | Acquired | Partial |
| 31 | Neuronetics | Depression medical devices | $120M | 3 | Undisclosed 2018 | $50M | IPO | NEA, Skyline Ventures | IPO | Full |
| 32 | Wayspring | Value-based addiction care | $117M | 6 | September 2021 | $75M | Growth / Series D | Valtruis, Centene, CareSource | Active | Partial |
| 33 | Author Health | Senior behavioral health care | $115M | 1 | June 2023 | $115M | Series A | General Atlantic, Flare Capital Partners, Oak HC/FT | Active | Full |
| 34 | Brightside Health | Virtual mood disorder care | $109M | 4 | March 2024 | $33M | Series C | S32, Kennedy Lewis, Time BioVentures | Active | Strong |
| 35 | Holmusk | Behavioral health data analytics | $109M | 7 | October 2023 | $30M | Series B extension / Strategic equity | Veradigm, Health Catalyst Capital, Heritas Capital | Active | Partial |
| 36 | Bicycle Health | Virtual opioid treatment | $104M | 5 | January 2025 | $17M | Series C / Growth | Questa Capital, SignalFire, JSL Health | Active | Strong |
| 37 | Grow Therapy | Therapy marketplace | $100M | 3 | Undisclosed 2023 | $30M | Series B | TCV, Sequoia, Base10 | Active | Partial |
| 38 | Octave | In-network therapy provider | $88M | 5 | February 2024 | $5M | Later-stage extension | Greycroft, Felicis Ventures, Health Velocity Capital | Active | Strong |
| 39 | InStride Health | Pediatric anxiety/OCD care | $86M | 3 | June 2026 | $30M | Series C | Echo Health Ventures, FMZ Ventures, General Catalyst | Active | Full |
| 40 | Boulder Care | Virtual addiction treatment | $85M | 4 | May 2024 | $35M | Series C | Advance Venture Partners, Stripes, Qiming Venture Partners | Active | Strong |
| 41 | NOCD | OCD specialty telehealth | $84M | 5 | January 2023 | $34M | Growth / Series C-like | Cigna Ventures, 7wireVentures, Longitude Capital | Active | Full |
| 42 | Two Chairs | Therapist matching network | $83M | 4 | April 2024 | $52M | Series C | Fifth Down Capital, Amplo, Bridge Bank | Active | Strong |
| 43 | Eleanor Health | Addiction and mental healthcare | $82M | 3 | April 2022 | $50M | Series C | General Catalyst, Warburg Pincus, Town Hall Ventures | Active | Strong |
| 44 | ieso | Digital CBT therapy | $77M | 5 | November 2021 | $53M | Series B | Morningside, Sony Innovation Fund, IP Group | Acquired | Partial |
| 45 | Valera Health | High-acuity virtual mental healthcare | $74M | 5 | March 2024 | $10M | Series B extension | Heritage Group, Cigna Ventures, Windham Venture Partners | Active | Partial |
| 46 | Delix Therapeutics | Neuroplastogen brain-disorder therapies | $70M | 1 | September 2021 | $70M | Series A | ARTIS Ventures, RA Capital Management, OMX Ventures | Active | Partial |
| 47 | Ophelia | Opioid treatment telehealth | $68M | 3 | December 2021 | $50M | Series B | Tiger Global, Menlo Ventures, General Catalyst | Active | Full |
| 48 | Brave Health | Medicaid virtual behavioral care | $61M | 3 | October 2022 | $40M | Series C | Town Hall Ventures, Union Square Ventures, City Light Capital | Active | Partial |
| 49 | Cartwheel Care | School-based youth mental health | $59M | 3 | August 2025 | $35M | Series B / private equity | General Catalyst, Menlo Ventures, Reach Capital | Active | Partial |
| 50 | Concert Health | Collaborative behavioral care | $58M | 3 | April 2022 | $42M | Series B | Define Ventures, Healthy Ventures, Town Hall Ventures | Active | Partial |
| 51 | Osmind | Neuropsychiatry EHR platform | $57M | 4 | May 2022 | $40M | Series B | DFJ Growth, Future Ventures, General Catalyst | Active | Full |
| 52 | NeuroFlow | Behavioral health integration | $55M | 4 | October 2022 | $25M | Series C / Growth | SEMCAP Health, Magellan Health, Builders VC | Active | Strong |
| 53 | Forta | AI-enabled autism therapy | $55M | 1 | January 2024 | $55M | Series A | Insight Partners, Exor Ventures, Alumni Ventures | Active | Full |
| 54 | Healios | Online youth mental health care | $54M | 5 | September 2024 | $5M | Extension / early-stage | Albion Capital, InHealth Ventures, Autism Impact Fund | Active | Strong |
| 55 | AnswersNow | Virtual ABA autism therapy | $51M | 2 | January 2026 | $40M | Series B | HealthQuest Capital, Left Lane Capital, Owl Ventures | Active | Partial |
| 56 | aptihealth | Higher-acuity virtual care | $50M | 4 | April 2023 | Undisclosed | Equity/warrants extension | Takeda Digital Ventures, Pivotal Life Sciences, Claritas Capital | Active | Partial |
| 57 | Numinus | Psychedelic-assisted therapy clinics | $50M | 4 | February 2024 | $4M | Public offering | Integrated V.C., MAPS, Eight Capital | IPO | Partial |
| 58 | Amae Health | Severe mental illness care | $50M | 4 | November 2025 | $25M | Series B | Altos Ventures, Quiet Capital, Cedars-Sinai Ventures | Active | Partial |
| 59 | Array Behavioral Care | Virtual psychiatry and therapy | $49M | 3 | January 2023 | $25M | Series C | CVS Health Ventures, Wells Fargo Strategic Capital, Health Velocity Capital | Active | Strong |
| 60 | Small Pharma | Short-duration psychedelic therapeutics | $49M | 7 | March 2021 | $46M | RTO private placement | Canaccord, Eight Capital, Haywood | Acquired | Partial |
| 61 | Freespira | At-home PTSD panic treatment | $49M | 6 | April 2024 | $23M | Series D | Lightspeed Venture Partners, Kleiner Perkins, Aphelion Capital | Active | Partial |
| 62 | firsthand | Serious mental illness support | $43M | 2 | February 2023 | $28M | Series B | GV / Google Ventures | Active | Partial |
| 63 | Meru Health | Therapist-supported digital mental healthcare | $42M | 3 | September 2021 | $30M | Series B | Industry Ventures, Freestyle VC, Bold Capital Partners | Active | Partial |
| 64 | Iris Telehealth | Telepsychiatry for health systems | $40M | 1 | April 2022 | $40M | Series B | Concord Health Partners, Columbia Pacific Advisors, Corewell Health Ventures | Active | Strong |
| 65 | Uwill | Campus mental health platform | $39M | 3 | May 2023 | $30M | Series A | Education Growth Partners | Active | Full |
| 66 | Little Otter | Family mental healthcare platform | $36M | 3 | February 2025 | $10M | Strategic funding | Pivotal Ventures, Torch Capital, Fiore Ventures | Active | Full |
| 67 | Tava Health | Employer mental health therapy | $33M | 3 | March 2024 | $20M | Series B | Catalyst Investors, Peterson Partners, Blue Heron Capital | Active | Full |
| 68 | Mantra Health | College mental health clinic | $32M | 4 | March 2023 | $5M | Series A extension | VMG Partners, Canaan Partners, City Light Capital | Active | Full |
| 69 | HelloSelf | Online therapy platform | $32M | 4 | March 2023 | $20M | Series B | Octopus Ventures, OMERS Ventures, Manta Ray Ventures | Active | Partial |
| 70 | Bend Health | Pediatric family mental care | $32M | 2 | March 2023 | $27M | Series A | Maveron, SteelSky Ventures, WVV Capital | Acquired | Partial |
| 71 | Ria Health | Alcohol treatment telehealth | $31M | 3 | February 2025 | $7M | Series B / Growth | Peloton Equity, SV Health Investors, SOSV | Active | Partial |
| 72 | PursueCare | Virtual addiction treatment | $31M | 4 | December 2023 | $20M | Series B | T.Rx Capital, Yamaha Motor Ventures, Seyen Capital | Active | Strong |
| 73 | SpectrumAi | Autism ABA data software | $29M | 2 | March 2023 | $20M | Series A | CVS Health Ventures, Cobalt Ventures, F-Prime Capital | Acquired | Full |
| 74 | NUE Life Health | Ketamine mental wellness platform | $26M | 2 | April 2022 | $23M | Series A / mixed financing | Obvious Ventures, Western Technology Investment | Active | Partial |
| 75 | Monument | Online alcohol treatment | $24M | 3 | February 2023 | $6M | Series A extension | Data Point Capital, VMG Partners, Red Sea Ventures | Active | Partial |
| 76 | Blackbird Health | Youth mental health care | $23M | 2 | February 2024 | $17M | Series A | Define Ventures, Frist Cressey Ventures, GreyMatter | Active | Partial |
| 77 | Affect Therapeutics | App-based addiction recovery | $22M | 2 | July 2023 | $16M | Series A | ARTIS Ventures, AlleyCorp, LifeArc Ventures | Active | Strong |
| 78 | Opya | Early autism intervention care | $22M | 3 | August 2021 | $15M | Series A | Panoramic Ventures, SoftBank Opportunity Fund, Raven One Ventures | Active | Partial |
| 79 | BehaVR | VR behavioral health therapeutics | $21M | 2 | December 2022 | $13M | Series B | Optum Ventures, Oxford Science Enterprises, Accenture Ventures | Acquired | Partial |
| 80 | Birches Health | Gambling addiction telehealth care | $20M | 2 | September 2025 | Undisclosed | Series A | AlleyCorp, General Catalyst, Will Ventures | Active | Partial |
| 81 | OxfordVR | Automated VR mental therapy | $19M | 3 | February 2020 | $13M | Series A | Optum Ventures, Luminous Ventures, Oxford Sciences Innovation | Acquired | Strong |
| 82 | Backpack Healthcare | Pediatric mental telehealth | $18M | 4 | May 2024 | $14M | Series A | PACE Healthcare Capital, ECMC, Techstars | Active | Partial |
| 83 | Marigold Health | Peer mental health support | $17M | 3 | June 2024 | $11M | Series A | Rock Health, Innospark Ventures, KdT Ventures | Active | Partial |
| 84 | Psyomics | AI mental health assessment | $17M | 4 | September 2025 | $7M | Pre-Series A | BGF, Cambridge Enterprise, Parkwalk Advisors | Active | Partial |
| 85 | Fort Health | Insurance pediatric mental care | $16M | 2 | November 2024 | $6M | Funding round | Twelve Below, Vanterra, Redesign Health | Active | Strong |
| 86 | Psylo | Psychedelic drug discovery | $14M | 3 | June 2024 | $8M | Seed | Tenmile, Palo Santo, Gaingels | Active | Strong |
| 87 | Awakn Life Sciences | Addiction-focused psychedelic therapeutics | $14M | 6 | March 2025 | <$1M | Post-IPO placement | Palo Santo, Iter Investments | Active | Partial |
| 88 | Journey Clinical | Psychedelic therapy infrastructure | $12M | 4 | January 2023 | $9M | Series A | Union Square Ventures, Fifty Years, PsyMed Ventures | Active | Partial |
| 89 | Flow Neuroscience | Depression brain-stimulation headset | $12M | 3 | August 2021 | $9M | Series A | Khosla Ventures, Swiss Health Ventures, Zühlke Ventures | Active | Full |
| 90 | GrayMatters Health | PTSD self-neuromodulation therapy | $10M | 1 | January 2022 | $10M | Series A | Otsuka Medical Devices | Active | Strong |
| 91 | Manatee | Family mental health platform | $9M | 4 | May 2024 | $2M | Latest equity round | Grand Ventures, SpringTime Ventures | Active | Partial |
| 92 | Sonara Health | Remote methadone monitoring | $6M | 3 | September 2025 | $1M | Strategic investment | Boomerang Ventures, Acumen America, First Trust Capital Partners | Active | Partial |
| 93 | DynamiCare Health | Addiction recovery rewards platform | $6M | 2 | July 2021 | $2M | Seed extension | Early Light Ventures, Hyperplane Capital, MEDA Angels | Active | Full |
| 94 | Innerwell | Psychedelic-assisted therapy platform | $3M | 1 | June 2022 | $3M | Pre-seed | Greycroft, Looking Glass Capital, Max Ventures | Active | Full |
| 95 | Clerkenwell Health | Psychedelic clinical trial CRO | $3M | 2 | October 2022 | $2M | Seed | Convergence Partners, Moonstone | Active | Strong |

This market map, featured in our mental health market deck, highlights top companies and startups in the mental health market
Key funding trends in the mental health market
Insights
- The mental health market is highly concentrated at the top, with the 10 most funded startups representing about 43% of disclosed funding in the filtered ranking.
- Psychedelic and neuropsychiatric drug developers are unusually important in this market, with atai, MindMed, Cybin, Compass, Bright Minds, Lykos, Beckley and Draig raising about $2.9B combined.
- Employer and payer-facing mental health platforms remain the strongest private digital health cohort, led by Lyra Health, Spring Health, Headway, Brightline, SonderMind, Brightside and Two Chairs.
- Public-market financing matters more in mental health than in many other digital health categories, especially for psychedelic, neurotechnology and therapeutic developers.
- Autism-focused care is becoming a meaningful funding cluster, with Cortica, Forta, AnswersNow, SpectrumAi and Opya showing strong investor interest in specialized pediatric care.
- Addiction treatment remains a clear subcategory, with Pelago, Bicycle Health, Boulder Care, Eleanor Health, Ophelia, Workit Health and PursueCare building scaled virtual or hybrid models.
- Recent funding activity is still visible after 2024, especially in psychedelics, neuroscience, behavioral health AI, pediatric care and high-acuity specialty mental healthcare.

As this chart shows, and as featured in our mental health market deck, search interest in men’s mental health has been rising steadily
A few word about our methodology
As you can see, we built a database that ranks startups in the mental health market based on their total cumulative fundraising. To create this ranking, we reviewed many sources and cross-checked information across multiple places.
Whenever possible, we prioritized official company communications, since official announcements are usually the most reliable source for funding amounts. When those were not available, we relied on reputable industry sources such as TechCrunch, Crunchbase, Financial Times or Forbes (to name a few).
We excluded random blogs, unverified websites, and any sources that could not be validated.
When funding rounds were announced in other currencies such as euros, Swiss francs, Singapore dollars, Australian dollars, or rupees, we converted them into approximate USD equivalents for consistency.
Sometimes different sources report slightly different numbers, or the exact round size is not fully disclosed. In those cases, we flag the uncertainty and assign a confidence label to each startup, visible in the last column.
Here is what they mean.
Full confidence: The company’s equity fundraising history can be reconstructed completely from public sources. The rounds, dates, amounts, and key investors are clearly identified, with no meaningful gaps.
Strong confidence: The fundraising history is largely complete and reliable. There may be a small missing detail, such as incomplete investor information or a minor round with limited data, but the overall record is clear.
Partial confidence: The main fundraising rounds can be identified, but the record is incomplete or somewhat mixed. Some rounds may be missing or certain funding events may be difficult to separate clearly.
Low confidence: Public information is too limited, inconsistent, or ambiguous to reliably reconstruct the company’s equity fundraising history.
When the confidence level is too low, we take a conservative approach and exclude the company from the ranking. We don’t want to include data that cannot be reliably verified.
This reflects how we conduct all our research, including the work behind our report covering the mental health market.
In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.
If you want the full detail on a specific calculation, feel free to contact us and we will gladly explain.
Finally, know that we update the dataset once per month, so come back here if you need fresh information.

This chart, featured in our mental health market deck, shows why Talkspace is winning in mental health
Related blog posts
- The most important recent news in the mental health market
- The most recent funding news in the mental health market
- What is new in the mental health market lately?
- The evolution of funding activity in the mental health market
- The main fundraising trends in the mental health market
- How big is the mental health market really?
- The full range of business models in the mental health market
Who is the author of this content?
NEW MARKET PITCH TEAM
We track new markets so founders and investors can move fasterWe build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.
How we created this content 🔎📝
At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.
So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.
Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.